Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

5.6%

1 terminated out of 18 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

75% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (3)
P 1 (6)
P 2 (5)

Trial Status

Recruiting9
Completed3
Not Yet Recruiting2
Active Not Recruiting2
Unknown1
Terminated1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT07082868Phase 1RecruitingPrimary

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

NCT06714370CompletedPrimary

Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study

NCT07198087Phase 1Active Not RecruitingPrimary

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

NCT07523737Phase 2RecruitingPrimary

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT05131022Phase 1Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT04830137Phase 1Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

NCT07410520Phase 2RecruitingPrimary

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

NCT03703167Phase 1CompletedPrimary

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

NCT04401774Phase 2CompletedPrimary

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

NCT07188077RecruitingPrimary

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT07198464Not ApplicableNot Yet RecruitingPrimary

Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma

NCT07074470Not ApplicableRecruitingPrimary

Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

NCT07014943Phase 2RecruitingPrimary

High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma

NCT04688151Phase 1Active Not RecruitingPrimary

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

NCT06946407Not ApplicableRecruitingPrimary

Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma

NCT06646211Phase 2Not Yet RecruitingPrimary

High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)

NCT04253496UnknownPrimary

Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)

NCT00710151TerminatedPrimary

Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors

Showing all 18 trials

Research Network

Activity Timeline